INHIBRx, Inc

Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. At Inhibrx, we utilize diverse methods of protein engineering to address the specific requirements of complex target and disease biology. Our proprietary protein engineering platforms can be harnessed for multivalent pathway stimulation and crosslinking of multiple target proteins, permitting exploration of diseases with complex underlying biology to develop breakthrough therapies that address unmet medical needs. Our commitment to revolutionizing patient care is demonstrated by our pipeline of promising candidates, which includes INBRX-101, -105, -106, and -109. Each of these candidates is being investigated across a range of diseases, including certain types of rare cancers (including sarcomas).
 
For more information, please visit www.inhibrx.com.